1. Gefitinib induces EGFR and α5β1 integrin co-endocytosis in glioblastoma cells
- Author
-
Stéphane Dedieu, Monique Dontenwill, Cristophe Schneider, Maxime Lehmann, Jessica Devy, Oleksandr Glushonkov, Nelly Etienne-Selloum, Marie-Cécile Mercier, Anne-Florence Blandin, Pascal Didier, Elisabete Cruz Da Silva, Laurence Choulier, Laboratoire de Bioimagerie et Pathologies (LBP), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Matrice extracellulaire et dynamique cellulaire - UMR 7369 (MEDyC), Université de Reims Champagne-Ardenne (URCA)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), and Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
[SDV]Life Sciences [q-bio] ,Integrin ,Endosomes ,Endocytosis ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,Gefitinib ,Cell Movement ,Cell surface receptor ,Cell Line, Tumor ,Glioma ,medicine ,Humans ,RNA, Small Interfering ,Protein Kinase Inhibitors ,Molecular Biology ,ComputingMilieux_MISCELLANEOUS ,Pharmacology ,0303 health sciences ,Epidermal Growth Factor ,biology ,Brain Neoplasms ,Chemistry ,Cell Membrane ,030302 biochemistry & molecular biology ,Cell migration ,Cell Biology ,medicine.disease ,respiratory tract diseases ,3. Good health ,ErbB Receptors ,Cancer cell ,Cancer research ,biology.protein ,Molecular Medicine ,RNA Interference ,Glioblastoma ,Tyrosine kinase ,Integrin alpha5beta1 ,medicine.drug - Abstract
Overexpression of EGFR drives glioblastomas (GBM) cell invasion but these tumours remain resistant to EGFR-targeted therapies such as tyrosine kinase inhibitors (TKIs). Endocytosis, an important modulator of EGFR function, is often dysregulated in glioma cells and is associated with therapy resistance. However, the impact of TKIs on EGFR endocytosis has never been examined in GBM cells. In the present study, we showed that gefitinib and other tyrosine kinase inhibitors induced EGFR accumulation in early-endosomes as a result of an increased endocytosis. Moreover, TKIs trigger early-endosome re-localization of another membrane receptor, the fibronectin receptor alpha5beta1 integrin, a promising therapeutic target in GBM that regulates physiological EGFR endocytosis and recycling in cancer cells. Super-resolution dSTORM imaging showed a close-proximity between beta1 integrin and EGFR in intracellular membrane compartments of gefitinib-treated cells, suggesting their potential interaction. Interestingly, integrin depletion delayed gefitinib-mediated EGFR endocytosis. Co-endocytosis of EGFR and alpha5beta1 integrin may alter glioma cell response to gefitinib. Using an in vitro model of glioma cell dissemination from spheroid, we showed that alpha5 integrin-depleted cells were more sensitive to TKIs than alpha5-expressing cells. This work provides evidence for the first time that EGFR TKIs can trigger massive EGFR and alpha5beta1 integrin co-endocytosis, which may modulate glioma cell invasiveness under therapeutic treatment.
- Published
- 2020
- Full Text
- View/download PDF